What Are Valion Bio Inc.'s Key Financial Figures?

Fiscal yearFY2024
ended December 31, 2024
FY2023
ended December 31, 2023
FY2022
ended December 31, 2022
Revenue$780,000$1 million$2 million
Operating income-$4 million-$8 million-$10 million
Operating margin-573.8%-701.1%-548.8%
Net income-$6 million-$8 million-$10 million
Net margin-725.0%-701.0%-548.7%
Operating cash flow-$6 million-$9 million-$9 million
Capital expenditures$0$118,000$11,000
Free cash flow-$6 million-$9 million-$9 million

Operating margin widened by 127.3 percentage points between fiscal 2023 and 2024, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$6 million against net income of -$6 million; cash generation fell short of reported earnings, which is worth reconciling in the cash flow statement.

Bar chart of Valion Bio Inc. revenue, operating income, net income for fiscal 2022 to 2024. In fiscal 2024, revenue was $780,000, operating income negative $4 million and net income negative $6 million.
Valion Bio Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.
Line chart of Valion Bio Inc. operating margin and net margin for fiscal 2022 to 2024. In fiscal 2024, operating margin was -573.8% and net margin was -725.0%.
Valion Bio Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.
Bar chart of Valion Bio Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2022 to 2024. In fiscal 2024, operating cash flow was negative $6 million, capital expenditures was $0, free cash flow was negative $6 million.
Valion Bio Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.

What Does Valion Bio Inc.'s Balance Sheet Show?

Cash and cash equivalents$2 million
Long-term debtNot reported
Total assets$3 million
Total liabilities$272,000
Shareholders' equity$3 million
Current ratio9.7x

Balance sheet values are as of the end of fiscal 2024. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.

Where These Numbers Come From

Every figure on this page is a value Valion Bio Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0000950170-25-043234 for fiscal year 2024). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.

Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.

Frequently Asked Questions

What was Valion Bio Inc.'s revenue in fiscal 2024?

Valion Bio Inc. reported revenue of $780,000 for the fiscal year ended December 31, 2024, according to its SEC filings.

What is Valion Bio Inc.'s operating margin?

Valion Bio Inc.'s operating margin was -573.8% in fiscal 2024: operating income of -$4 million on revenue of $780,000.

How much free cash flow did Valion Bio Inc. generate?

Operating cash flow of -$6 million less capital expenditures of $0 gives free cash flow of -$6 million for fiscal 2024.

References

Related Pages